The potentiation of fluoxetine by buspirone is described in three cases of treatment-resistant depression. All three patients improved markedly with very few side-effects from the medication. The possibility of synergy between drugs that affect serotonin reuptake inhibition, 5HT1A receptors and 5HT2 receptors is discussed.
References
1.
StarkP., HardisonC.D.A review of multicentre controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depression.J Clin Psychiatry1985; 46: 53–58.
2.
FontaineR., ChouinardG.Fluoxetine in long term maintenance treatment of obsessive compulsive disorder.Psychiatry Ann1989; 19: 88–91.
3.
EisonA.S., TempleD.L.Jr.Buspirone, review of its pharmacology and current perspective on its mechanism of action.Am J Med1986 (Suppl. 3D) 80; 1–8.
4.
BernsteinJ.G.Handbook of drug therapy in psychiatry, second edition.Littleton MA: PSG Publishing,1988: 1159.
5.
PeroutkaS.J., SleightA.J.The clinical utility of pharmacological agents that act at serotonin receptors.J Neuropsychiatry;1989; 1(3): 253–262.
